22. Anticoagulation in high bleeding risk cancer patients - Dr Nolukholo Ncete

DOACs for the prevention and acute treatment of CAT - Video abstract [ID 271411]Подробнее

Managing Bleeding Events in Patients Receiving Direct Oral AnticoagulantsПодробнее

Updates in anticoagulation for cancer associated thrombosis: what, when and for whomПодробнее

Cancer Associated Thrombosis (CAT): risk factors and improving awarenessПодробнее

#99 Bleeding vs. Clotting Risk: Gray Matters SegmentПодробнее

Oral Anticoagulants in Cancer Patients: Mixed-Results and a Lesson about Trial EnrichmentПодробнее

Clot Chronicles: Updated Guidance on Managing Bleeding in Patients on Oral AnticoagulationПодробнее

The Clot Thickens: anticoagulation in oncology patientsПодробнее

Prediction and Prevention of Cancer-Associated Thromboembolism (CAT)Подробнее

Anticoagulation and risk of bleeding with Atrial FibrillationПодробнее

Apixaban reduced thromboembolism risk in cancer patientsПодробнее

Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care to Improve OutcomesПодробнее

Anticoagulation in the thrombocytopenic patientПодробнее

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapyПодробнее

Dalteparin Thromboprophylaxis in Cancer PatientsПодробнее

Restarting anticoagulation after a bleedПодробнее

Alok Khorana: Rivaroxaban Prevents Cancer-Associated VTEПодробнее

Benefits of apixaban among venous thromboembolism patients with active cancerПодробнее

The increased risk of thromboembolism in cancerПодробнее